The UPC's approach to added matter and functional claims (Abbott v. Sibio Technology, UPC_CoA_382/2024)
The recent decision in Abbott v Sibio Technology ( UPC_CoA_382/2024 ) offers valuable insights into the UPC's approach to the...
top of page
Securing market protection for cell therapies: Patents versus regulatory exclusivity
Cell therapies represent incredibly exciting science and the opportunity to treat previously intractable diseases. Cell therapies...
Beyond the process: Securing robust IP protection for cell therapies
Cell therapy represents one of the most exciting fields of innovation, with the potential to provide long-term cures for previously...
The benefits and pitfalls of drug manufacturing IP (T 2543/22)
The Board of Appeal decision in T 2543/22 relates to a manufacturing method for preparing a therapeutic peptide. The Board of Appeal...
A new mode of administration is a new specific medical use (but not necessarily inventive) (T 0295/22)
The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a...
EBA's preliminary opinion in G1/24: "the description and the figures can be referred to in the course of claim interpretation"
The Enlarged Board of Appeal (EBA) has issued its preliminary opinion in the closely watched referral G1/24 relating to the role of the...
The description of a patent should "always" be used to interpret the claims (DexCom vs. Abbott, UPC_CFI_230/2023)
The Paris Local Division of the Unified Patent Court (UPC) first substantive decision on patent validity in DexCom v Abbott (...
bottom of page